Signal, buried.
Thousands of trials, abstracts and filings land every month. The one move that changes your strategy is in there — you just can't surface it in time.
COMPETITIVE INTELLIGENCE · ONCOLOGY-ONLY
Oncology competitive intelligence, before the landscape moves.
Prognyx turns the noise of trials, readouts, deals and regulatory moves into continuous, sourced, decision-ready intelligence — mapped around your pipeline, not a database you have to mine.
3,000+ trials watched
72h move-to-brief
1 focus — oncology
[ 01 ] THE PROBLEM
The field moves faster than any team can track.
Tools, not answers.
A six-figure database hands you data to mine. A consulting project hands you a deck — once. Neither watches your back on a Tuesday afternoon.
Priced for giants.
Enterprise intelligence is built for big-pharma budgets. The biotech with the most riding on a single asset is the one left flying blind.
3,000+
oncology trials in motion, watched to the primary record
72h
from competitor move to a brief on your desk
1
therapeutic focus — oncology, and nothing else
[ 02 ] WHAT PROGNYX DOES
Oncology competitive intelligence, on continuous watch.
Not a portal you log into. Not a report you wait six weeks for. A standing intelligence function for your pipeline — reading every trial, readout, label and deal that touches your space, and telling you what it means and what to do.
- Continuous. The watch never stops between deliverables.
- Sourced. Every claim traces back to the primary record — NCT, label, abstract, filing.
- Decision-ready. The so-what and the now-what, not a data dump.
- Tailored. Scoped to your assets, mechanisms and indications.
COMPETITIVE BRIEF
LIVE WATCH
KRAS G12C — second-line NSCLC
Competitor readoutESMO 2026
Threat levelElevated
Window to act~6 weeks
78
A rival's confirmatory data lands before your filing. Here's the angle, the risk to your positioning, and the three moves on the table.
SOURCED · ClinicalTrials.gov · ESMO abstract · FDA label
[ 03 ] HOW IT WORKS
From noise
to a decision,
in four moves.
Define
We map your competitive set — targets, mechanisms, indications and the assets that can move your value.
SCOPEWatch
We track trials, congress readouts, regulatory actions, deals and publications — straight to the primary source.
MONITORSynthesize
We turn it into what it means for you and what to do next — sharp, sourced, no filler.
ANALYZEDecide
You get briefs your team actually reads and forwards — plus answers on demand when the field shifts.
ACTThe next move,
first.
Start with a sample→
[ 04 ] WHY PROGNYX
Not a database. Not a $150k deck. Your analyst.
Prognyx
Data platforms
Consulting
Continuous watch
Tailored to your pipeline
Decision-ready (the so-what)
Oncology-deep
Days, not weeks
Accessible to a single-asset biotech
We don't out-database the giants. We out-matter them — on the one question they can't answer for you: what do I do about this, on my molecule, this week?
[ 05 ] FROM THE WATCHTOWER
Oncology intelligence, in the open.
BeOne’s CLL Phase 3 puts sonrotoclax against venetoclax plus acalabrutinib
The recruiting 500-patient NCT07277231 trial turns BeOne’s sonrotoclax-zanubrutinib strategy from a broad CLL program into a direct fixed-duration BCL2/BTK combination…
Read briefing →
Zipalertinib's REZILIENT3 hits its PFS endpoint in first-line EGFR exon 20 lung cancer; full data land 13…
Taiho and Cullinan report a Phase 3 first-line PFS win at interim; the hazard ratio and median PFS are not yet disclosed and are set for IASLC on 13 September 2026…
Read briefing →
Per Endpoints News, Bristol Myers Squibb claims Phase 2 success for a GPRC5D-directed CAR-T in multiple…
Endpoints News reports the win frames a GPRC5D CAR-T as a post-relapse option for myeloma patients who progress after CAR-T therapy.
Read briefing →
AstraZeneca reports durvalumab-tarlatamab maintenance improves survival in first-line ES-SCLC
The company's 8 September press release reports statistically significant overall and progression-free survival gains from adding tarlatamab to durvalumab first-line…
Read briefing →
Per Endpoints News, Novartis pauses immunology and neuroscience CAR-T studies after three patient deaths
Per Endpoints News, Novartis has halted immunology and neuroscience studies of an experimental CAR-T therapy after three patient deaths.
Read briefing →
Pfizer licenses its terminated CD228 ADC PF-08046031 to Medicus Pharma while keeping the patents and over $1B…
Prognyx read: a large pharma divesting an ADC rather than buying one — Pfizer hands off a Seagen-derived asset it had already shelved (per Endpoints and Fierce Biotech)…
Read briefing →[ 06 ] THE OFFER
See the next move first.
Tell us the one asset you'd want watched. We'll send back a sample competitive brief on it — sourced, sharp, no strings. If it's not the clearest read you've had on your space, you owe us nothing.
How Prognyx knows this
Every claim is built from primary sources only — and traces back to a document you can open. No opinion you can't check.
Who's behind it
Rali Filali — founder of Prognyx · M.D. candidate. Independent — no platform or bank behind the read. Every brief is audited against the primary record before it reaches you. Competitive analysis of public information — not medical or investment advice.
Retainers from $2,000/month — scoped to your pipeline, a fraction of a $100k+ enterprise platform. Or start with a one-off pilot brief ($1,500–3,000). What's included
ONCOLOGY COMPETITIVE INTELLIGENCE · PROGNYX